Table 5.
FDA-approved therapeutic drugs for prostate cancers
| Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
| Bicalutamide (Casodex) | Ani pharms | AR antagonist | Advanced prostate cancer | 10/04/1995 | S |
| Nilutamide (Nilandron) | Concordia | AR antagonist | Metastatic prostate cancer | 09/19/1996 | S |
| Enzalutamide (Xtandi) | Astellas | AR antagonist | mCRPC | 08/31/2012 | P |
| Apalutamide (Erleada) | Janssen | AR antagonist | Prostate cancer | 02/14/2018 | P |
| Darolutamide (Nubeqa) | Bayer | AR antagonist | Prostate cancer | 7/30/2019 | P |
| Triptorelin pamoate (Trelstar) | Verity | GnRH agonist | Advanced prostate cancer | 06/15/2000 | S |
| Abarelix (Plenaxis) | Speciality | GnRH receptor antagonist | Advanced prostate cancer | 11/25/2003 | P |
| Degarelix acetate (Firmagon) | Ferring | GnRH receptor antagonist | Advanced prostate cancer | 12/24/2008 | S |
| Relugolix (Orgovyx) | Myovant | GnRH receptor antagonist | Prostate cancer | 12/18/2020 | P |
| Cabazitaxel (Jevtana kit) | Sanofi | Microtubule-stabilizing agent | Prostate cancer | 06/17/2010 | P |
| Abiraterone acetate (Zytiga) | Janssen | CYP17A1 inhibitor | mCRPC | 04/28/2011 | P |
| Radium RA 223 dichloride (Xofigo) | Bayer | α-particle-emitting radiopharmaceutical | mCRPC | 05/15/2013 | P |
AR Androgen receptor; CYP17A1 Cytochrome P450 17A1; GnRH Gonadotropin-releasing hormone; mCRPC Metastatic castration-resistant prostate cancer; O Orphan; P Priority; S Standard